Blocking the interaction between interleukin-33 and regulatory T cells may serve as a new therapeutic target for cancers associated with chronic inflammatory diseases.
Top news of the day across the health care landscape.
MDNA55 prolonged survival in IL4R-positive patients with recurrent glioblastoma in a phase 2b clinical trial.
Prevalence of cognitive impairment has increased among the HIV population while services for diagnosing and treating afflicted individuals remains scarce.
The sBLA is based on data showing significant improvement in overall survival and progression-free survival in patients with advanced renal cell carcinoma.
Data from an analysis of multiple phase 3 studies highlight improvements in mobility, self-care, and usual activities for patients with moderate-to-severe psoriasis taking secukinumab (Cosentyx).
The study through Penn State College of Medicine adds to existing research on the benefits of medical cannabis in cancer cases.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.